Jaguar health announces topline results of investigator-initiated phase 2 study of crofelemer for prevention of chemotherapy-induced diarrhea (cid) in breast cancer patients

Crofelemer is a novel, oral plant-based non-opioid antidiarrheal medication san francisco, ca / accesswire / november 19, 2021 / jaguar health, inc. (nasdaq:jagx) today announced topline results of the third-party, investigator-initiated phase 2 halt-d trial evaluating crofelemer for the prevention of chemotherapy-induced diarrhea (cid) in her2-positive breast cancer patients being treated with trastuzumab, pertuzumab and a taxane.1 these therapies are known to cause cid in up to 80% of breast cancer patients, reaching grade 3 (requiring hospitalization) in 8-12% of patients.2-5 cid can have a negative impact on quality of life, particularly when it persists through much of the course of chemotherapy, and may result in stopping cancer treatment. there are no medications currently approved for cid.
JAGX Ratings Summary
JAGX Quant Ranking